drugset / Trial / NCT00405366
Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
Phase 0
Completed
30 enrolled
UNC Lineberger Comprehensive Cancer Center
Amgen · collabBayer · collabDoris Duke Charitable Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying the side effects and how well sorafenib works in treating patients undergoing surgery for stage II, stage III, or stage IV kidney cancer.
Timeline
- Start
- 2006-11
- Primary completion
- 2009-06
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |